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Abstract 
 
 
 
Objective 
 
 
 
In rheumatoid arthritis, composite outcomes constructed from a combination of 
outcome measures are widely used to enhance responsiveness (sensitivity to change) 
and comprehensively summarize response.  WOMAC pain is the primary outcome 
measure in many osteoarthritis (OA) trials. Information from other outcomes, such as 
rescue medication use, and other WOMAC subscales, could be added to create  
composite outcomes, but the sensitivity of such a composite has not been tested. 
 
Method 
 
 
 
We used data from a completed trial of Tanezumab for knee OA (NCT00733902). The 
WOMAC questionnaire and rescue medication use were measured at multiple time 
points, up to 16 weeks. Pain and rescue medication outcomes were standardised and 
combined into 3 composite outcomes via principal components analysis to produce one 
score (composite outcome) and their responsiveness was compared to WOMAC pain, 
the standard. We pooled all treatment doses of Tanezumab into one ‘treatment’ group, 
for simplicity, and compared this to the control group (placebo). 
 
Results 
 
 
 
The composite outcomes showed modestly but not statistically significantly greater 
responsiveness when compared to WOMAC pain alone. Adding information on rescue 
medication to the composite improved responsiveness. While improvements in 
sensitivity were modest, the required sample sizes for trials using composites was 20- 
40% less than trials using WOMAC pain alone 
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Conclusion 
 
 
 
Combining information from related, but distinct, outcomes considered relevant to a 
particular treatment improved responsiveness, could reduce sample size requirements 
in OA trials and might offer a way to better detect treatment efficacy in OA trials. 
 
 
 
 
 
 
 
 
 
Keywords: Osteoarthritis; Outcomes; Pain; Sensitivity to Change; Responsiveness. 
 
 
 
Running headline: Sensitivity to Change of Pain Oucomes 
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1 Significance & Innovations: 
 
 
 
2 • This study attempts to evaluate meaningful ways of combining single outcomes in a way that 
3 improves responsiveness, gaining more power to detect treatment effects without collecting more 
4 data. 
5 • This can improve efficiency in future clinical trials, as it helps improve detection of smaller 
6 treatment effects with fewer participants. 
7 • Combining outcomes appears to produce composites with greater sensitivity to change than 
8 constituent parts. 
9 
 
 
 
10 
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11 Introduction 
 
 
 
12 Clinical trialists have a tendency to measure many outcomes. Several of these outcomes (often 
 
13 deliberately) cover overlapping ‘domains’, attempting to ensure that the ‘signal’ of a true change in an 
 
14 outcome following an intervention is captured. Pain is a good example; researchers will often use a 
 
15 variety of similar pain-related outcomes in interventional trials. 
 
 
 
16 Pain is a complex, multidimensional measure(1,2), and generating just one scale or item that adequately 
 
17 captures most, if not all, aspects of pain is challenging. Furthermore, as pain is strongly related to 
 
18 functional limitation(3), the most appropriate pain outcome might cover aspects of both pain and 
 
19 function. The optimal clinical trial pain outcome(s) should additionally be sensitive to change following 
 
20 an intervention, by which we mean the outcome’s ability to detect a change, often also termed an 
 
21 outcome’s responsiveness(4), discriminating well between a true signal, (treatment effect) and noise 
 
22 (random variation). 
 
 
 
23 Composite outcomes are a way of combining (often related) indices or scores to form one overall 
 
24 outcome. This approach, which has been used in many disease areas, including osteoarthritis(5), 
 
25 rheumatoid arthritis(6–8) and asthma(9), may improve the capture of a domain more completely as it 
 
26 takes account of more information than one outcome alone. Pain measurement appears particularly 
 
27 suited to this approach, given its complexity. Combining information from several different domains may 
 
28 improve a composite’s ability to detect a change when one truly occurs, and therefore ‘responsiveness’ 
 
29 may also be improved. 
 
 
 
30 Constructing Composites: Available Methods 
 
 
 
31 There are several methods for combining outcomes into composites. Some of these facilitate domain 
 
32 coverage; others increase responsiveness. Ideally, the method used should improve both. The simplest 
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33 method of combining two or more outcomes is through summing or averaging them(5). This method 
 
34 assumes that the constituent outcomes have equal weighting in the composite, and that units from the 
 
35 constituent outcomes are comparable and exchangeable. 
 
 
 
36 A second method of combining multiple outcomes is through the use of weights to assign ‘importance’ of 
 
37 constituent outcomes. The composite is produced my multiplying each constituent outcome by its weight, 
 
38 and then summing these scores. An example of this is the DAS28(6,7). Weights can be derived from a 
 
39 variety of sources, including statistical modelling (as with the DAS), but also from group consultation, for 
 
40 example via a Delphi exercise (10–14). 
 
 
 
41 Another data-driven approach uses principal components analysis, a data-reduction method which 
 
42 inherently concentrates as much variance from constituent outcomes into as few factors as possible. This 
 
43 method may produce a composite outcome which more completely captures the variance from an 
 
44 underlying multidimensional process, such as pain. 
 
 
 
45 Theoretically, combining several outcomes purporting to measure aspects of pain and its consequences, 
 
46 such as function loss and rescue medication use, should increase domain coverage (as each outcome 
 
47 contributes some information about the pain signal), and therefore responsiveness. Since all of the 
 
48 contributing outcomes should measure that same latent factor (pain), the analysis model used should 
 
49 assume a priori a one factor solution, rather than generating multiple outcomes. This way, we can 
 
50 combine all outcomes related to pain into one composite outcome, which will hopefully show maximal 
 
51 responsiveness in pain. 
 
 
 
52 This study sought to combine several pain outcomes using principal components analysis, taken from a 
 
53 large completed clinical trial of a treatment that reduced pain, and compare the relative responsiveness 
 
54 of these composites to the uncombined WOMAC pain subscale score alone, to establish whether the 
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55 inclusion of additional pain information improves responsiveness following administration of an 
 
56 intervention. 
 
 
 
57 Assessment of responsiveness is optimal in certain trial designs. The ideal trial should contain a 
 
58 treatment arm with an intervention which is known to truly change the construct of interest (pain, for 
 
59 example); a control arm which is known to truly not change the construct of interest, and at least two 
 
60 (ideally more) time points in both arms, over which the change in each outcome is assessed. The trial we 
 
61 selected had these features. If the outcome of interest is not changed during the study, then it is not 
 
62 possible to assess responsiveness. 
 
 
 
63 
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64 Methods 
 
 
 
65 The data used in this study were from a large completed clinical trial of Tanezumab in participants with 
 
66 knee osteoarthritis (NCT00733902). This trial was a 32 week four-arm parallel-group phase III trial, 
 
67 comparing 3 doses of tanezumab (2.5, 5, or 10 mg) against placebo. Participants were observed at 
 
68 baseline, 2, 4, 8, 12, 16, 24, and 32 weeks; we used data from the 2 week visit to the 16 week visit, as data 
 
69 for rescue medication use were collected only at these visits. For simplicity, we pooled all tanezumab 
 
70 doses (2.5mg, 5mg, and 10mg) together into one ‘treatment’ group and compared this to the placebo 
 
71 group. Further details regarding the trial’s design as well as data on unstandardised outcome scores in 
 
72 have been published previously(15). This study is a reanalysis of completed clinical trial data, and is 
 
73 exempt from ethical review under the NHS Health Research Authority Guidelines. 
 
 
 
74 Variable Definitions 
 
 
 
75 Single Outcomes: 
 
 
 
76 We used the following pain-related outcomes featured in NCT00733902: WOMAC pain, stiffness, and 
 
77 function subscales; and number of rescue medication pills taken per week. 
 
 
 
78 Composite Outcomes: 
 
 
 
79 Including information from at least two, and up to four outcomes in each composite gives 11 possible 
 
80 combinations available from which composites could be generated. We generated a total of three 
 
81 composite outcomes which were felt to be the most meaningful and pragmatic of the 11 possible 
 
82 combinations. Composite one consisted of the WOMAC pain subscale plus rescue medication. Composite 
 
83 two consisted of all three WOMAC subscales (pain, stiffness, and function). Composite three consisted of 
 
84 all three WOMAC subscales, plus the rescue medication outcome. Composite outcomes were derived by 
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85 including the selected combination of variables in a principal components analysis (PCA), which assumed 
 
86 a one factor solution. We opted for PCA, given its propensity to maximise the amount of variance 
 
87 captured in the first (and in this case, only) derived component. We assumed that all included outcomes 
 
88 measured different aspects of one latent (multidimensional) pain variable, and forcing a one component 
 
89 solution therefore ensured that this variable was derived. Angst et al. (2005) found that unrestricted 
 
90 factor analysis of individual WOMAC items established new factors which drew from both the pain and 
 
91 function subscales, and merged them together(16), supporting this idea. It also simplifies the analysis, as 
 
92 it creates only one composite outcome, rather than allowing many composite factors to be generated in 
 
93 each PCA model. We constructed three PCA models, each generating one of three composite outcomes. 
 
94 Rotation of the factor solution (of any type, varimax, promax, or other) was not indicated in our 
 
95 approach, as a one factor solution has only one possible orientation. 
 
 
 
96 We pooled together data from all study visits in the analysis models (rather than using data from baseline 
 
97 only, for example) assuming that it was best to include the maximum available number of observations in 
 
98 the PCA models. 
 
 
 
99 Analysis Approach 
 
 
 
100 All composite outcome measures were compared to the WOMAC pain, assuming this as the standard. 
 
 
 
101 All of the single outcomes (WOMAC pain subscale score, WOMAC function subscale score, WOMAC 
 
102 stiffness subscale score, and number of rescue medication pills taken) were standardised prior to 
 
103 inclusion in the factor analysis models, and the composites (composites one, two, and three detailed 
 
104 above) were also standardised. Having all variables standardised (as z-scores) allows direct comparison 
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105 of outcomes with different units. 
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106 We used a random-effects panel linear regression (via SAS’s PROC MIXED) to assess change in the 
 
107 standardised outcome score over time, with outcome type, study visit, and treatment group (either 
 
108 tanezumab or placebo) and all possible interactions, as predictor variables. Constructing the data in ‘long 
 
109 format’, and using outcome type as a categorical dummy-coded variable allows direct testing for 
 
110 differences in responsiveness between all outcomes in one statistical model (further detail on model 
 
111 terms in online appendix). SAS’s PROC MIXED command uses a likelihood-based approach, treating 
 
112 missing observations as missing-at-random. 
 
 
 
113 We used linear combinations of coefficients from the regression model (using SAS PROC ESTIMATE) to 
 
114 produce the difference in standardised change between the WOMAC pain subscale and each composite 
 
115 outcome, at each study time point. This formally tests whether the outcomes differed from the WOMAC 
 
116 pain subscale in terms of responsiveness at each of the five time points in the study. 
 
 
 
117 Statistical analysis used SAS® software version 9.3; (SAS Institute Inc., Cary, NC, USA). A nominal alpha 
 
118 
 
119 
level of 0.05 was used for all confidence intervals. 
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120 
121 
122 
Results 
 
Study Sample Demographics 
 
123 At baseline, the placebo group (N=172) comprised 119 females (69.2%), with a mean age of 62.2 years, 
 
124 Kellgren-Lawrence grades 2, 3 and 4 of 39.5%, 47.7%, and 12.8% respectively, mean WOMAC pain 
 
125 subscale score (0-10) of 7.1, and mean WOMAC function subscale score (0-10) of 6.6. The pooled 
 
126 tanezumab group (N=518) at baseline had 301 females (58.1%), with a mean age of 61.4 years, Kellgren- 
 
127 Lawrence grades 2, 3 and 4 of 38.4%, 46.3%, and 14.5% respectively, mean WOMAC pain subscale score 
 
128 
 
129 
(0-10) of 7.1, and mean WOMAC function subscale score (0-10) of 6.8. 
 
130 Ten participants had missing observations for all outcomes at the time points of interest, giving a total 
 
131 sample size for this analysis of 680, compared with the original trial sample size of 690, with 509 in the 
 
132 pooled tanezumab group, and 171 in the placebo group. Data for the 680 included patients could have 
 
133 been collected on 7 outcomes, at 5 time points, giving a total of 23,800 possible observations. Of these, 
 
134 
 
135 
20,597 were actual observed data points, with 3,203 observations missing (13.5%). 
 
136 Principal Components Analysis Results 
 
137 The PCA process generated composites with component loadings shown in table 1. WOMAC pain and 
 
138 stiffness subscales consistently had  the  greatest, and  indeed equal, loading, closely followed by  the 
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139 WOMAC function subscale. When all 3 WOMAC subscale variables were included in the PCA model (in 
 
140 
 
141 
composite 3), the rescue medication’s loading dropped considerably. 
 
142 Composite Outcome Performance 
 
143 All composites showed responsiveness greater than at least some of their constituent outcomes on their 
 
144 own, and this difference was consistent across multiple time points (figure 1). Composite one showed 
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145 consistently greater responsiveness than the WOMAC pain subscale alone. The remaining two composites 
 
146 displayed responsiveness greater than all other constituent outcomes, except the WOMAC stiffness 
 
147 subscale. None of the single or composite outcomes showed consistently statistically significantly better 
 
148 
 
149 
responsiveness than that observed in the WOMAC pain subscale at the chosen alpha level (table 3). 
 
150 We next examined the impact of the observed differences in responsiveness on sample size requirements 
 
151 for a hypothetical new trial featuring the same design (table 2). For example, the WOMAC pain subscale 
 
152 between-groups standardised change at four weeks was a difference of -0.37. A hypothetical new trial of 
 
153 identical design observing this between-group difference for the WOMAC pain outcome would require 
 
154 236 participants (118 per group) to achieve 80% power with a two sided 5% type-I error rate. In 
 
155 contrast, using composite 1 (i.e. including information on rescue medication as well as the WOMAC pain 
 
156 subscale score) as the primary outcome which had an observed difference at four weeks of -0.41, the 
 
157 same trial would need 190 participants (95 per group) to achieve 80% power with this difference - a 
 
158 saving of 46 participants. When the observed differences between treatments is smaller, the reduction in 
 
159 sample size was more extreme: the WOMAC pain difference at 16 weeks (-0.26) would require 476 
 
160 participants for 80% power in a hypothetical new trial, compared to only 364 participants when using 
 
161 
 
162 
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163 Discussion 
 
164 We found that composite outcomes generally had moderately greater responsiveness in a large OA trial 
 
165 than WOMAC pain – the usual standard outcome of these trials. That suggests if one of these composite 
 
166 outcomes were used as the primary outcome in an OA trial, fewer subjects would be needed to 
 
167 
 
168 
demonstrate treatment efficacy. 
 
169 The improvements in responsiveness did not meet the criteria for a statistically significant difference, but 
 
170 perhaps a more salient measure of their import was to determine what effect using these outcomes had 
 
171 on the sample size needed to be likely to show statistically significant effects of treatment vs. placebo. We 
 
172 found that the reduction in sample size was substantial, ranging from roughly 20 to 40%. Thus, 
 
173 composites could substantially diminish the sample sizes needed in an osteoarthritis trial whose main 
 
174 
 
175 
outcome is pain. 
 
176 Eigenvalues from the three composite models all were much greater than the 1.0 cut-off typically used to 
 
177 select retained factors in a PCA model(17), and a large proportion of the variance in the outcomes was 
 
178 captured by the first component in the PCA model, as anticipated (table 1). The second factor listed in the 
 
179 model output (which was not extracted in this analysis) in all cases had an eigenvalue much less than 1, 
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180 lending support to the idea that the selected correlated outcomes are well captured in in one ‘pain’ 
 
181 
 
182 
component. 
 
183 Rescue medication use, whilst contributing to the ‘pain’ component the least (table 1), appeared to still 
 
184 improve responsiveness: composites including this outcome - composites one (WOMAC pain plus rescue 
 
185 medication use) and three (WOMAC pain, stiffness, and function, plus rescue medication) - showed slight 
 
186 improvements in responsiveness compared with composite 2, which excluded rescue medication. 
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187 
 
 
 
188 Aside from the methods used to combine outcomes, the method chosen to assess responsiveness is also 
 
189 important(18,19). Several methods are commonly cited to quantify responsiveness: the standardised 
 
190 response mean (SRM)(20), the effect size (ES)(18), either Glass' Δ(21) or Cohen’s d(22) (depending on 
 
191 the standard deviation used), or Guyatt’s responsiveness index (GRI) (23). All of these methods have two 
 
192 important limitations. First, all methods calculate responsiveness over two time points, and cannot easily 
 
193 be generalised to a study which has three or more time points. This prevents assessment of how 
 
194 responsiveness may fluctuate over time, and limits the definition of responsiveness only to the 
 
195 magnitude of change relative to its variance, rather than the speed of response. Second, these methods do 
 
196 not directly assess statistical inference; a; differences in responsiveness coefficients are assessed 
 
197 descriptively only. Methods have been proposed (modified jackknife procedure (5,24,25), bootstrapping 
 
198 (26)) to address this issue, but other methods which directly perform statistical inference as part of the 
 
199 method generating the coefficient are desirable. 
 
 
 
200 Our approach made use of z-scores (standard scores) (27). Converting each outcome’s absolute score to 
 
201 a z-score allows direct comparison of change in an outcome at different time points, thereby allowing 
 
202 direct assessment of change over time, and direct comparison between different outcomes. This 
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203 
 
 
 
204 
methodology has been used previously to compare non-composite outcomes(28). 
 
 
 
205 The PCA approach assumes that an intervention will alter several related aspects of a common construct, 
 
206 therefore combining all the multidimensional aspects of pain together to form one outcome should 
 
207 increase responsiveness. However, if one aspect of pain is changed alone, then the inclusion of other 
 
208 aspects of pain which do not change may decrease the sensitivity of the composite. Our finding that the 
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209 WOMAC stiffness subscale was the most sensitive outcome may fit this explanation: It may be, at least in 
 
210 this trial, that the WOMAC stiffness subscale was the closest correlate to the actual latent pain factor 
 
211 altered by the treatment, hence the greatest responsiveness, and inclusion of other subscales or rescue 
 
212 medication eroded it. Our finding may be limited to tanezumab alone – as the agent’s anti-nerve growth 
 
213 
 
214 
factor effect may have a greater impact on the stiffness sensation than other pain subscales(15,29). 
 
215 Freemantle et al. (2003) provide a comprehensive discussion on the use of composite outcomes in 
 
216 clinical trials(30), highlighting how composite outcomes can obfuscate changes in constituent outcomes. 
 
217 This is particularly problematic when outcomes are unrelated (for example, a composite which combines 
 
218 cardiovascular events and mortality), although they note the statistical advantages (increased power and 
 
219 sensitivity) that arise through the construction of composites(30,31). This discussion highlights how both 
 
220 the outcomes used in the composite, and the method by which they are combined, are important. The 
 
221 present study combined the three WOMAC subscales, pain, stiffness, and function, into one composite 
 
222 outcome. We assumed that these three subscales were all aspects of the same construct (pain). The PCA 
 
223 (table 1) produced extremely high factor loading in all three subscales, supporting this notion - at least in 
 
224 this trial. In contrast, if pain and function were discrete constructs, then the PCA should fail, with either 
 
225 pain or function alone loading on the latent factor. Both Ryser et al. (1999), and Angst et al. (2005) found 
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226 close association between pain and function WOMAC subscales, partly supporting this finding(16,32). In 
 
227 addition, an item overlap analysis on the WOMAC pain and function subscales by Stratford et al. (33) 
 
228 found significant item redundancy between the pain and function subscales, and a further factor analysis 
 
229 on the WOMAC items found clustering of items not by subscale, but by activity(34), suggesting that the 
 
230 
 
231 
WOMAC subscales are not distinct. 
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232 We surmised that responsiveness in the outcomes may differ over time, as well as in magnitude. In this 
 
233 study, all outcomes appeared to have responded at the same time point, and retained their relative 
 
234 positions consistently over time (none of the outcome’s trajectories crossed over each other over time, 
 
235 
 
236 
figure 1). 
 
237 There are limitations to this analysis. We observed only very few statistically significant differences 
 
238 between outcomes. The trial was designed to observe a difference in the primary outcome between 
 
239 treatment groups (a relatively large difference), and was not designed to compare treatment differences 
 
240 between outcomes (much smaller differences). Therefore even the large sample size in the trial provides 
 
241 relatively low power to detect differences between outcomes. Ideally in future, this analysis would be 
 
242 designed in to the trial prior to commencement, with appropriate sample size and power. We also 
 
243 allowed many interaction effects, which increased model-to-data fit at the expense of statistical power. 
 
244 We have assumed in this analysis that the covariate structure of the pain outcomes, and the relationship 
 
245 between the outcomes and the latent (unobserved) pain outcome are consistent between studies, and 
 
246 therefore generalisable across other studies. This is a relatively strong assumption, requiring validation 
 
247 
 
248 
in other datasets to allow wider generalisation to other trials with confidence. 
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249 While the aim of this approach was to include additional information on pain from rescue medication 
 
250 data, this outcome may not be optimal. Rescue medication is a challenging variable to collect data on 
 
251 accurately, and therefore the likelihood is that measurement error of this variable is high. This may 
 
252 provide an explanation for why the improvement in sensitivity of composites including rescue 
 
253 
 
254 
medication are small. 
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255 Even though the between-outcome differences were not statistically significant, even a small 
 
256 improvement in responsiveness can impact upon sample size calculations (table 3). This produces gains 
 
257 in efficiency without collecting any novel data simply by reanalysing the data using a method which 
 
258 produces a more sensitive, and therefore efficient, outcome. We could have included further assessment 
 
259 of other composites made from different combinations of the 11 possible from the four single outcomes 
 
260 used, for example one using WOMAC pain plus WOMAC stiffness. We opted to create the three 
 
261 composites which would have the most pragmatic impact on outcome inclusion/exclusion when 
 
262 designing a trial. The alternative, generating all 11 possible combinations and comparing them head to 
 
263 
 
264 
head, would further reduce the statistical power to discern differences between composite outcomes. 
 
265 The PCA approach to generating a composite outcome by its nature produces a unitless score. While the 
 
266 generated score may have increased responsiveness compared to one of the constituent outcomes, it is 
 
267 more difficult to ascertain the clinical importance of the observed effect, in comparison to another 
 
268 outcome with meaningful units and an agreed minimally clinical importance difference (MCID). A 
 
269 downside PCA composites is the absence of known values of MCID, but this could be established if a 
 
270 
 
271 
specific composite were widely used. 
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272 The choice of primary and secondary outcomes in this trial limited the choice of outcomes available to 
 
273 combine into a composite. Ideally, we would have preferred to use a trial featuring a wider range of pain 
 
274 outcomes, particularly the more recent KOOS(35) and ICOAP(36) questionnaires; however a dataset 
 
275 
 
276 
 
277 
using these outcomes amongst others, and featuring the other requirements was not available. 
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278 The present findings are similar to our previous paper, which used data from two other completed 
 
279 clinical trials of non-drug interventions(28). In both of these trials, the WOMAC stiffness subscale also 
 
280 showed an increased, but non-statistically-significant, degree of responsiveness compared to the other 
 
281 two WOMAC subscales. Angst et al. (2001; 2008), in contrast, found the WOMAC pain subscale to be the 
 
282 most sensitive outcome to change(5,24), however these studies did not examine rescue medication, and 
 
283 used a two-time point approach only. Further, the two studies previously analysed were both 
 
284 prospective cohort studies lacking a control group. Thus, optimizing the detection of treatment effect 
 
285 
 
286 
over placebo was not possible in the two Angst et al. analyses. 
 
287 In summary, we investigated whether collapsing several measures of a multidimensional construct into 
 
288 one composite outcome through the use of PCA could help improve responsiveness following an 
 
289 intervention. Adding rescue medication alongside other elements of the WOMAC showed improved 
 
290 
 
291 
 
292 
responsiveness, greater than the constituent outcomes. 
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Figure Legend 
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Figure 1: Sensitivity to Change of Single Pain-Related Outcomes from the Tanezumab Trial. Values plotted 
are the control-treatment differences in standard score, at different study time points. More negative 
values indicate increased sensitivity to change 
